0001415889-24-000770.txt : 20240105
0001415889-24-000770.hdr.sgml : 20240105
20240105160536
ACCESSION NUMBER: 0001415889-24-000770
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240104
FILED AS OF DATE: 20240105
DATE AS OF CHANGE: 20240105
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Brazzell Romulus K
CENTRAL INDEX KEY: 0001298079
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38150
FILM NUMBER: 24516243
MAIL ADDRESS:
STREET 1: C/O INSPIRE PHARMACEUTICALS, INC.
STREET 2: 4222 EMPEROR BLVD., SUITE 200
CITY: DURHAM
STATE: NC
ZIP: 27703
FORMER NAME:
FORMER CONFORMED NAME: Brazzell Kim
DATE OF NAME CHANGE: 20040722
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: KALA BIO, Inc.
CENTRAL INDEX KEY: 0001479419
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 270604595
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1167 MASSACHUSETTS AVENUE
CITY: ARLINGTON
STATE: MA
ZIP: 02476
BUSINESS PHONE: 781-996-5252
MAIL ADDRESS:
STREET 1: 1167 MASSACHUSETTS AVENUE
CITY: ARLINGTON
STATE: MA
ZIP: 02476
FORMER COMPANY:
FORMER CONFORMED NAME: Kala Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20091223
4
1
form4-01052024_090119.xml
X0508
4
2024-01-04
0001479419
KALA BIO, Inc.
KALA
0001298079
Brazzell Romulus K
C/O KALA BIO, INC.
1167 MASSACHUSETTS AVENUE
ARLINGTON
MA
02476
false
true
false
false
SEE REMARKS
0
Common Stock
2024-01-04
4
A
0
6500
0
A
93090
D
Common Stock
2024-01-04
4
S
0
1617
6.74
D
91473
D
Stock Option (right to buy)
7
2024-01-04
4
A
0
29300
0
A
2034-01-03
Common Stock
29300
29300
D
Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continued employment with the Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 4, 2025, as to 1/3 of the shares underlying the RSUs on January 4, 2026 and as to the final 1/3 of shares underlying the RSUs on January 4, 2027
Includes 86,756 unvested RSUs and 782 shares acquired under the Issuer's Amended and Restated 2017 Employee Stock Purchase Plan on July 3, 2023.
This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs granted on January 4, 2023 and January 4, 2021.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.73 to $6.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
Includes 82,306 unvested RSUs.
This option was granted on January 4, 2024 and vests over four years beginning on the vesting commencement date of January 4, 2024, with 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter until January 4, 2028, subject to the Reporting Person's continued employment with the Issuer.
Head of Research and Development and Chief Medical Officer
/s/ Eric Trachtenberg, Attorney-in-Fact
2024-01-05